Trevi Therapeutics has linked its oral, extended-release formulation of the opioid analgesic nalbuphine to reduced cough frequency in idiopathic pulmonary fibrosis (IPF) patients, prompting it to wrap ...
NEW HAVEN, Conn., Oct. 3, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) ...
NEW HAVEN - Trevi Therapeutics, Inc. (NASDAQ:TRVI) has scheduled an End-of-Phase 2 meeting with the FDA in the first quarter of 2026 to discuss its chronic cough program for patients with idiopathic ...
The Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough First pivotal trial is on track to initiate in the second quarter of ...
Investing.com - Oppenheimer raised its price target on Trevi Therapeutics (NASDAQ:TRVI) to $24.00 from $23.00 on Friday, while maintaining an Outperform rating on the stock. The new target represents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results